Trump Must End Germany’s Healthcare Freeloading
The article discusses the disparity in drug prices between the United States and Germany, highlighting how Americans pay significantly more for medications. It argues that Germany's regulatory practices allow them to negotiate lower prices, which ultimately shifts costs to American consumers. The piece concludes by noting President Trump's stance on addressing this trade imbalance through potential tariffs on Germany.
- ▪The United States develops half of all new medicines but pays two to three times more than other developed countries.
- ▪Germany's regulatory framework allows them to negotiate lower prices for U.S.-made drugs, impacting American consumers.
- ▪President Trump is advocating for fair pricing practices and has warned Germany about potential tariffs due to their pricing strategies.
Opening excerpt (first ~120 words) tap to expand
Trump Must End Germany’s Healthcare Freeloading Ashley Herzog | 8:47 PM on May 26, 2026 AP Photo/Nam Y. Huh Here’s a paradox for you to think over: half of all new medicines are developed in the United States, yet Americans pay two to three times more for those medicines than people in other developed countries. Advertisement googletag.cmd.push(function () { googletag.display("div-gpt-300x250_3"); //googletag.pubads().refresh([gptAdSlot["div-gpt-300x250_3"]]) }); If it sounds unfair, that’s because it is. The United States is the world’s leader when it comes to pharmaceutical innovation. American firms regularly research, develop, and market life-saving medicines that are then distributed all over the world. These new drugs don’t come on the cheap.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at PJ Media.
Discussion
0 commentsMore from PJ Media
